BMY - Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers | Benzinga
The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications.
On Thursday, the administration is reportedly set to introduce a blueprint enabling the National Institutes of Health to more extensively exercise "march-in rights" – a policy enabling the seizure of patents from drug manufacturers whose products rely on research funded by the federal government.
This framework will delineate instances when the agency might invoke this authority and advocate considering a drug's price in making such determinations, Politico noted, citing the sources.
The Biden administration has concluded that it ...